Indications
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Composition
- Active substance
- mercaptamine bitartrate
- International name (INN)
- mercaptamine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Procysbi
- Active substance
- mercaptamine bitartrate
- ATC code
- A16AA04
- Therapeutic area
- Cystinosis